Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2018-07-31
Target enrollment:
Participant gender:
Summary
This is a multicentre, randomized, double-blind, placebo-controlled, parallel-group Phase II
trial of twelve weeks of KBP-042 administered as daily s.c. injections in subjects with Type
2 Diabetes Mellitus with inadequate glycaemic control while treated with a stable dose of
metformin.
The trial is planned to be performed in Czech Republic, Denmark, Moldova, Poland, Romania and
United Kingdom